The UN Children’s Fund UNICEF has announced that it has signed an agreement with the medical company Pfizer on behalf of the COVAX countries for the delivery of the vaccine against Covid-19 for the year 2021.
The vaccine is expected to begin shipping as early as the first quarter of 2021.
The delivery date depends on countries receiving Pfizer-BioNTech vaccine doses via COVAX confirming that they are ready to accept Pfizer / BioNTech vaccines. Conversely, these countries would also have to meet the requirements set by the COVAX facility.
More vaccination doses than previously promised
The current supply agreement made it possible for UNICEF to procure more vaccine doses in 2021 than the maximum of 40 million that the COVAX countries had agreed to under the Advance Purchase Agreement (APA) with Pfizer / BioNTech, according to the press release from UNICEF.
Pfizer / BioNTech’s Covid-19 vaccine, which was the first to receive WHO emergency approval on December 31, 2020, must be stored in an ultra-cold chain. UNICEF and its partners are working around the clock to help governments provide the necessary cold chain funds for the storage and distribution of a wide variety of COVID-19 vaccines that require different storage methods.
Second long-term supply contract
This contract is the second long-term supply agreement that UNICEF has signed with an anti-Covid-19 vaccine manufacturer on behalf of the COVAX countries. UNICEF recently signed an agreement with the Serum Institute of India for access to two vaccines obtained through technology transfer from AstraZeneca and Novavax, which were subject to WHO approval.
The COVAX initiative was founded in June at the global vaccination summit and is led by the “Coalition for Epidemic Preparedness Innovations” (CEPI) and the WHO together with UNICEF. It aims to provide corona vaccines to the most vulnerable 20 percent of the population in every country. By the end of 2021, at least 2 billion doses of the approved anti-Covid-19 vaccines are expected to be delivered to enable participating economies to protect frontline health and social workers as well as other high-risk and vulnerable groups.
For 92 countries with low incomes, the costs for the vaccination doses are covered, for richer countries COVAX serves as a fall-back option in the event of supply bottlenecks.
The aim of the COVAX agreement is to make safe and effective Covid-19 vaccines available and affordable for all countries in the world, regardless of their income level.
Natasha Kumar has been a reporter on the news desk since 2018. Before that she wrote about young adolescence and family dynamics for Styles and was the legal affairs correspondent for the Metro desk. Before joining The Times Hub, Natasha Kumar worked as a staff writer at the Village Voice and a freelancer for Newsday, The Wall Street Journal, GQ and Mirabella. To get in touch, contact me through my email@example.com 1-800-268-7116